CoChat

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity

Wharton, Sean, Lingvay, Ildiko, Bogdanski, Pawel, Duque do Vale, Ruben, Jacob, Stephan, Karlsson, Tobias, Shaji, Chaithra, Rubino, Domenica, Garvey, W. Timothy · 2025 · New England Journal of Medicine

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Background Oral semaglutide at a dose of 25 mg may provide an alternative treatment option to injectable semaglutide (2.4 mg) and higher-dose oral semaglutide (50 mg) for persons with overweight or obesity. Methods In a 71-week, double-blind, randomized, placebo-controlled trial conducted at 22 sites in four countries, we enrolled persons without diabetes who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or higher or a BMI of 27 or higher with at least one obesity-related complication. The participants were randomly assigned in a 2:1 ratio to receive oral semaglutide (25 mg) or placebo once daily, plus lifestyle interventions. The coprimary end points at week 64 were the percent change in body weight and a reduction of 5% or more in body weight; confirmatory secondary end points included reductions in body weight of 10% or more, 15% or more, and 20% or more and the change in the Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function score. Results A total of 205 participants were randomly assigned to receive oral semaglutide, and 102 to receive placebo. The estimated mean change in body weight from baseline to week 64 was -13.6% in the oral semaglutide group and -2.2% in the placebo group (estimated difference, -11.4 percentage points; 95% confidence interval, -13.9 to -9.0; P Conclusions Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in…

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa2500969

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 156

Metadata

Authors
Wharton, S., Lingvay, I., Bogdanski, P., Duque do Vale, R., Jacob, S., Karlsson, T., Shaji, C., Rubino, D., & Garvey, W. T.
Affiliations
  • University of Toronto (CA)
  • The University of Texas Southwestern Medical Center (US)
  • Department of Treatment of Obesity, Metabolic Disorders, and Clinical Dietetics, Poznań University of Medical Sciences, Poznań, Poland
  • Novo Nordisk, Søborg, Denmark
  • Department of Internal Medicine, Endocrinology, and Diabetology, Cardiometabolic Institute, Villingen-Schwenningen, Germany
  • Novo Nordisk (Denmark) (DK)
  • Novo Nordisk (India) (IN)
  • Washington Center for Weight Management and Research (US)
  • University of Alabama at Birmingham (US)
Venue
New England Journal of Medicine
Published
2025-09-18
Volume
393
Issue
11
Pages
1077-1087
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4414160143
Cited by
142
References
12
Citations by year
2026: 127 · 2025: 15
FWCI
79.21
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novo Nordisk A/S
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
oral semaglutide, obesity, overweight, weight loss, GLP-1 receptor agonists, gastrointestinal adverse effects, lifestyle intervention, obesity-related comorbidities, non-diabetic adults, weight regain after weight loss
MeSH terms
Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Life Style, Male, Middle Aged, Obesity, Quality of Life, Weight Loss, Body Mass Index, Treatment Outcome, Anti-Obesity Agents, Overweight, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.